(Q36582682)

English

Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis

scientific article published on September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

type-1 diabetes

0 references

author name string

Kenneth L McCall

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Deeatra Craddock

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Krystal Edwards

3

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1297-1306

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

The renin angiotensin system as a therapeutic target to prevent diabetes and its complications

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Strategies to prevent type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Estimation of a common effect parameter from sparse follow-up data

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1297

21 January 2018

Identifiers

10.1592/PHCO.26.9.1297

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36582682&oldid=1638563519"